tradmap

SION Financials Sionna Therapeutics, Inc.

2 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Financial health

  • The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
Revenue & net income
-$75M -$38M $0 2024 2025
RevenueNet income
Margins (gross / operating / net)
0% 50% 100% 2024 2025
GrossOperatingNet
Free cash flow (CFO − capex)
-$67M -$33M $0 2024 2025
Free cash flow
Cash vs total debt
$0 $29M $58M 2024 2025
CashTotal debt
Cash flow: operating / investing / financing
-$127M $39M $206M $0 2024 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 -$75M -$67M $58M
2024 -$62M -$53M $38M

Frequently asked questions

Is SION growing its revenue and profit?

See the revenue and net-income charts above for Sionna Therapeutics, Inc.'s multi-year trend.

How much debt does SION have?

As of FY2025, Sionna Therapeutics, Inc. reported — of total debt against $58M of cash.

What is SION's profit margin?

In FY2025, gross margin was —, operating margin —, and net margin —.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.